To identify microbial strains for live biotherapeutic products (LBPs) targeting Clostridioides difficile infection (CDI) using a computational pipeline and metagenomic datasets, emphasizing the potential for improved treatment options.
Key Findings:
Constructed a CDI-related microbial genome catalog comprising 3741 nrMAGs, which may inform future therapeutic strategies.
Identified protective nrMAGs including strains from Dorea formicigenerans, Oscillibacter welbionis, and Faecalibacterium prausnitzii, with potential implications for clinical applications.
Some protective nrMAGs correlate with successful fecal microbiota transplantation (FMT) outcomes, suggesting avenues for enhancing FMT efficacy.
Interpretation:
The study provides a framework for the rational design of LBPs targeting CDI, emphasizing the critical role of strain-level analysis in understanding microbial contributions to health and disease.
Limitations:
The mechanisms of action for FMT and LBPs are not fully understood, which may limit the applicability of findings.
Potential transmission of undetected pathogens through FMT remains a concern, necessitating further investigation.
The ecological principles behind the selection of microbial strains in approved products are unclear, indicating a need for more research.
Conclusion:
This research paves the way for the computational design of LBPs against CDI and potentially other enteric infections, underscoring the necessity for further exploration of microbial strain functions to optimize therapeutic outcomes.
